Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox

Trends in Pharmacological Sciences

Volumn 27, Issue 9, 2006, Pages 475-481

  Langmead, Christopher J ^a   Christopoulos, Arthur ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 (4 BUTYL 1 PIPERIDINYL) 1 (2 METHYLPHENYL) 1 BUTANONE; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 5 CHLORO 3 ETHYL 1H INDOLE 2 CARBOXYLIC ACID [2 (4 PIPERIDIN 1 YLPHENYL)ETHYL]AMIDE; 7 HYDROXYIMINOCYCLOPROPAN[B]CHROMEN 1A CARBOXYLIC ACID ETHYL ESTER; AC 260584; AC 42; ADENOSINE A1 RECEPTOR AGONIST; ALCURONIUM; ALPHA CYCLOPROPYL 4 PHOSPHONOPHENYLGLYCINE; AMN 082; CANNABINOID RECEPTOR AGONIST; CGP 7930; CHEMOKINE RECEPTOR AGONIST; CHOLINERGIC RECEPTOR STIMULATING AGENT; ESTER DERIVATIVE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR AGONIST; GALLAMINE; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; HORMONE RECEPTOR STIMULATING AGENT; IBUTAMOREN; N (3 CHLOROPHENYL)CARBAMOXYLOXY 2 BUTYLNYLTRIMETHYLAMMONIUM CHLORIDE; N,N' DIBENZHYDRYLETHANE 1,2 DIAMINE; ORG 27569; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING AFFINITY; DRUG RECEPTOR BINDING; PRIORITY JOURNAL; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 33747181100     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.07.009     Document Type: Review

References (47)

1. Venter J.C., et al. The sequence of the human genome. Science 291 (2001) 1304-1351
2. Drews J. Drug discovery: a historical perspective. Science 287 (2000) 1960-1964
3. Kenakin T. G-protein coupled receptors as allosteric machines. Receptors Channels 10 (2004) 51-60
4. Neubig R.R., et al. International Union of Pharmacology committee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 55 (2003) 597-606
5. May L.T., and Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol. 3 (2003) 551-556
6. Stockton J.M., et al. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol. 23 (1983) 551-557
7. Ehlert F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33 (1988) 187-194
8. Clark A.L., and Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors. Br. J. Pharmacol. 58 (1976) 323-331
9. 2 receptors. Eur. J. Pharmacol. 316 (1996) 27-32
10. Lazareno S., and Birdsall N.J. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48 (1995) 362-378
11. Christopoulos A. Overview of Receptor Allosterism. Curr. Prot. Pharmacol. (2000) 1.21.1-1.21.45
12. May L.T., et al. Allosteric modulation of G protein-coupled receptors. Curr. Pharm. Des. 10 (2004) 2003-2013
13. Litschig S., et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 55 (1999) 453-461
14. Hall D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58 (2000) 1412-1423
15. B receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol. Pharmacol. 60 (2001) 963-971
16. Price M.R., et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68 (2005) 1484-1495
17. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4 (2005) 919-927
18. Mathiesen J.M., et al. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol. Pharmacol. 68 (2005) 393-402
19. Porter R.H., et al. Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity. J. Pharmacol. Exp. Ther. 315 (2005) 711-721
20. Zahn K., et al. Allosteric modulation of muscarinic receptor signaling: alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J. Pharmacol. Exp. Ther. 301 (2002) 720-728
21. 2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators. J. Pharmacol. Exp. Ther. 312 (2005) 382-390
22. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15 (2001) 598-611
23. 1 receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol. Pharmacol. 69 (2006) 236-246
24. 1 muscarinic receptor. Mol. Pharmacol. 61 (2002) 1297-1302
25. 1 muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. Mol. Pharmacol. 56 (1999) 1031-1041
26. 1 muscarinic receptors. Br. J. Pharmacol. 126 (1999) 735-745
27. Sur C., et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13674-13679
28. Kenakin T.P. Pharmacologic Analysis of Drug-Receptor Interaction (1997), Lippincott-Raven, Philadelphia, PA
29. o protein stoichiometry. Mol. Pharmacol. 54 (1998) 899-906
30. Arunlakshana O., and Schild H.O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 14 (1959) 48-58
31. Motulsky H.J., and Christopoulos A. Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting (2004), Oxford University Press, New York
32. Sachpatzidis A., et al. Identification of allosteric peptide agonists of CXCR4. J. Biol. Chem. 278 (2003) 896-907
33. Mitsukawa K., et al. A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18712-18717
34. Christopoulos A., and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54 (2002) 323-374
35. 3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 303 (2002) 1044-1051
36. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov. 1 (2002) 198-210
37. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 349-379
38. 1 muscarinic acetylcholine receptor without indusing adaptive changes. Program No. 149.5. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience
39. Bruns R.F., and Fergus J.H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38 (1990) 939-949
40. Holst B., et al. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signalling. Mol. Endocrinol. 19 (2005) 2400-2411
41. B receptor. J. Biol. Chem. 279 (2004) 29085-29091
42. Kinney G.G., et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 313 (2005) 199-206
43. Goudet C., et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 378-383
44. Birdsall N.J., et al. The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart. Br. J. Pharmacol. 78 (1983) 257-259
45. Jakubik J., et al. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8705-8709
46. 2 acetylcholine receptor. Eur. J. Biochem. 251 (1998) 659-666
47. 2 ACh receptor. Am. J. Physiol. Cell Physiol. 281 (2001) C1251-C1258